Topping estimates on Wall Street, Abbott (NYSE:ABT) posted a hefty beat yesterday with its second-quarter financial results. Driving the company’s growth was, in part, its diabetes business unit – sales jumped nearly 40% compared to Q2 in 2017 thanks largely to its sensor-based glucose monitoring system, Freestyle Libre.
“Libre offers a true mass-market opportunity with its unique combination of affordability, accessibility and ease of use and it’s achieving a level of patient adoption that’s unprecedented in the industry with more than 800,000 current users globally,” CEO Miles White said in a call with analysts.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.